Point72 Hong Kong LTD Anavex Life Sciences Corp. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $6,861 - $9,915	771 New	771 $8,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $29,700 - $52,168	-4,063 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$9.74 - $17.69 $48,174 - $87,494	-4,946 Reduced 54.9%	4,063 $50,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $91,624 - $126,526	5,428 Added 151.58%	9,009 $156,000
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $60,232 - $92,210	3,581 New	3,581 $64,000
Q2 2021 Aug 16, 2021	SELL	$10.16 - $28.86 $13,716 - $38,961	-1,350 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.17 - $16.13 $6,979 - $21,775	1,350 New	1,350 $20,000

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.